This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Albiero, R. Articles by Colombo, A. Search for Related Content PubMed PubMed Citation Articles by Albiero, R. Articles by Colombo, A. Related Collections Chronic ischemic heart disease Catheter-based coronary interventions: stents Coronary imaging: angiography/ultrasound/Doppler/CC

(Circulation. 2000;101:2454.)
© 2000 American Heart Association, Inc.

Brief Rapid Communications

Edge Restenosis After Implantation of High Activity ³²P Radioactive ß-Emitting Stents

Remo Albiero, MD; Takahiro Nishida, MD; Milena Adamian, MD; Antonio Amato, RN; Marco Vaghetti, MD; Nicola Corvaja, MD; Carlo Di Mario, MD, PhD; Antonio Colombo, MD

From Emodinamica Centro Cuore Columbus, Milan, Italy.

Correspondence to Remo Albiero, MD, EMO Centro Cuore Columbus, Via M. Buonarroti 48, 20145 Milan, Italy. E-mail albire{at}micronet.it

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—A high restenosis rate has been reported at the edges ("edge restenosis") of ³²P radioactive stents with an initial activity level of 3 to 12 µCi. This edge effect might be due to balloon injury and to a low dose of radiation at the stent margins. The aim of this study was to evaluate whether the implantation of ³²P radioactive stents with a higher activity level (12 to 21 µCi) combined with a nonaggressive stent implantation strategy could solve the problem of edge restenosis.

Methods and Results—We compared the results of lesions treated with single radioactive BX stents with an activity of 12 to 21 µCi (group 2, n=54 lesions) with the results of lesions treated by single radioactive BX stents with an initial activity level of 3 to 12 µCi (group 1, n=42 lesions). There were no procedural events. At the 6-month follow-up, no myocardial infarctions, deaths, or stent thromboses had occurred. Intrastent binary restenosis was 0% in group 1 versus 4% in group 2 (n=2, both at the ostium of the right coronary artery, P=NS). Intrastent neointimal hyperplasia was significantly lower in group 2 than in group 1. The intralesion (intrastent plus peri-stent) restenosis rate was 38% in group 1 versus 30% in group 2 (P=NS).

Conclusions—Single ³²P radioactive stents with an initial activity level of 12 to 21 µCi reduced intrastent neointimal hyperplasia compared with stents of 3 to 12 µCi, but they did not solve the problem of edge restenosis, even if a nonaggressive stent implantation strategy was used.

Key Words: radioisotopes • stents • restenosis • coronary disease

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
In patients with coronary artery disease treated with ³²P radioactive ß-emitting stents with an initial activity of 3 to 12 µCi, no intrastent restenosis was observed at the 6-month angiographic follow-up.¹ However, the intralesion restenosis rate was >40% due to restenosis at the stent edges ("edge restenosis").¹ This edge effect might be due to a low dose of radiation at the stent margins² combined with systematic balloon injury in the reference segments, especially when the balloon was oversized and inflated at high pressures (aggressive stent implantation strategy).

The purpose of this study was to evaluate whether ³²P radioactive stents with higher activity levels (12 to 21 µCi) combined with a nonaggressive stent implantation strategy could solve the problem of edge restenosis.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
The characteristics of the radioactive BX 15-mm long stent (Isostent) mounted on a 20-mm-long, compliant balloon and of the isotope (³²P) used in this study have been previously described.¹ A calculation of the dose of radiation delivered by each stent implanted was performed as recommended³ using the method proposed by Janicki et al.² Inclusion criteria for enrollment in this study have been previously reported.¹ The angiographic results of the lesions treated at our center from October 1998 to April 1999 by single radioactive BX stents with an initial activity of 12 to 21 µCi (group 2: 54 lesions, 40 patients) were compared with the results of the lesions previously treated with single radioactive BX stents with an activity of 3 to 12 µCi (group 1: 42 lesions, 40 patients). The additional lesions treated with >1 stent (group 1: 22 lesions, 17 patients; group 2: 22 lesions, 19 patients) were excluded.

The technique used to implant the radioactive stents in group 1 has been previously reported.¹ In group 2, a nonaggressive stent implantation technique was used. Lesion predilatation was performed with a nonoversized balloon, and the balloon used to deploy the stent was inflated at 8 to 10 atm; postdilatation was performed using a shorter balloon inflated at high pressure inside the stent to avoid mechanically damaging the reference segments outside the stent.

After stenting, patients received long-term treatment with aspirin (325 mg daily) plus ticlopidine (250 mg twice daily) or clopidogrel (75 mg daily) for 3 months. Angiographic and intravascular ultrasound (IVUS) analyses were performed as previously described.¹ Intrastent and intralesion restenosis, death, myocardial infarction, stent thrombosis, and target lesion revascularization were defined as previously reported.^{1 4 5 6}

Statistical Analysis
Statistical analysis was performed using the StatView statistical package (StatView 5, SAS Institute). Continuous, normally distributed data were expressed as mean±SD. Comparisons of continuous variables between groups were performed using ANOVA techniques. Subgroup comparisons of categorical variables were performed by the Fisher exact test or the ² test. Differences were considered statistically significant at P<0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Clinical and Procedural Characteristics
Patient and procedural characteristics are shown in Table 1. Most of the treated lesions (>77%) were de novo lesions. Because of the less aggressive stent implantation strategy, the final balloon size and balloon-to-artery ratio were smaller, although the difference was not statistically significative, in group 2 than in group 1.

View this table: [in this window] [in a new window]   Table 1. Clinical and Procedural Characteristics

Clinical Events
At the 6-month follow-up, no myocardial infarctions, deaths, or stent thromboses had occurred. Target lesion revascularization, which was performed in all lesions with angiographic restenosis even if the patients were asymptomatic and had no objective evidence of ischemia, was 38% in group 1 and 30% in group 2.

Quantitative Angiographic and IVUS Analysis
Table 2 summarizes the quantitative angiographic results. There were no differences between the groups, except for lesion length, which was shorter in group 2 than in group 1. Because of the less aggressive stent implantation strategy, there was a trend for a smaller final minimum lumen diameter and acute gain in group 2 than in group 1. In both groups, intralesion restenosis was 30%; it mainly occurred as a focal restenosis at the edge of the stent (33% in group 1 versus 26% in group 2, P=NS). Two examples of proximal edge restenosis that occurred in group 2 are shown in Figure 1. Intrastent restenosis was absent in group 1 and occurred in 2 lesions (4%) in group 2; these 2 lesions were both at the ostium of the right coronary artery, as shown in Figure 2. A total occlusion at follow-up, which was not associated with clinical events, was observed in 2 patients (5%) in group 1.

View this table: [in this window] [in a new window]   Table 2. Quantitative Angiographic Results

View larger version (116K): [in this window] [in a new window]   Figure 1. Proximal edge restenosis 6 months after implantation of a radioactive stent with an initial activity level >12 µCi. In one patient, baseline angiography (A) demonstrates a tight stenosis in the proximal obtuse marginal branch. (B) Final result after implantation of a 20-µCi radioactive stent. At 6-month follow-up (C), there is no late loss inside the stent but a tight stenosis exists at the proximal edge of the stent. D, Final results in a second patient after implantation of a 15.72-µCi radioactive stent. At 6-month follow-up (E), there is no intimal hyperplasia inside the stent (documented by IVUS), but a tight stenosis exists at the proximal edge of the stent. Dotted lines indicate the vessel segment length where the stent was placed.

View larger version (123K): [in this window] [in a new window]   Figure 2. Pattern of restenosis in the 2 patients (4%) in group 2 at 6-month follow-up who had intrastent restenosis after implantation of a radioactive stent with an initial activity level of 18.16 µCi (A) and 12.36 µCi (B). Magnified views of areas shown in dotted lines are shown in C and D. Restenosis occurred in both patients at the ostium of the right coronary artery. Note that in the first patient, the proximal edge of the stent was placed in the aorta (C; outlined with dotted lines).

Intrastent plaque volume, as calculated by quantitative IVUS measurements, was significantly lower (P<0.01) in group 2 (4.4±5.6 mm³, n=32 lesions) than in group 1 (15.1±14.1 mm³, n=33 lesions). As shown in Figure 3, late lumen loss in the first 3 mm from the proximal and distal margins of the 12 to 21 µCi radioactive stents with edge restenosis was mainly due to remodeling (shrinkage of the vessel), and only in the first 1 mm from the proximal edge of the stent it was due to a similar amount of remodeling and intimal hyperplasia.

View larger version (24K): [in this window] [in a new window]   Figure 3. Plot of mean late lumen loss, tissue growth, and remodeling (in mm2) in lesions treated with 12 to 21 µCi radioactive stents with edge restenosis (proximal edge, n=8; distal edge, n=5) in which serial IVUS measurements were available. CSA indicates cross-sectional area; prox, proximal; and dist, distal.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The results of this study indicate that single, 15-mm-long, ³²P radioactive ß-emitting BX stents with an initial activity level of 12 to 21 µCi are more effective than 3 to 12 µCi stents in reducing intrastent neointimal hyperplasia, as measured by IVUS; the potential mechanisms by which this effect occurs have been previously described.¹ No myocardial infarctions, death, or stent thrombosis were observed at the 6-month follow-up. However, although a nonaggressive stent implantation strategy was used, the problem of edge restenosis was not solved.

Mechanism of Edge Restenosis
In this study, the edge restenosis in 12 to 21 µCi radioactive stents that were implanted using a nonaggressive strategy was mainly due to remodeling. This result differs from our prior observations¹ in 3 to 12 µCi radioactive stents implanted using an aggressive strategy, in which edge restenosis was mainly due to tissue growth. Thus, by increasing the initial stent activity level and limiting the balloon-induced injury outside the stent, there was a reduction of edge restenosis related to plaque growth but not of that related to negative remodeling.

Future Directions
To reduce the problem of edge restenosis, 2 different modifications of the existing ³²P radioactive BX stent are under investigation: (1) the hot-ends stent and (2) the cold-ends stent. The hot-ends stent, which has a higher activity level at its proximal and distal ends, might diminish the problem of edge restenosis related to tissue growth and/or remodeling by extending the area of irradiation beyond the balloon-injured area outside the stent. However, if merely subtherapeutic levels of radiation are sufficient to induce proliferation/remodeling in uninjured tissue,⁷ increasing the activity at the stent ends would only relocate the restenotic zone further from the stent. Lengthening the stent with a nonradioactive cold-ends stent might also diminish the edge effect related to negative remodeling, which was demonstrated in this study to be the principal mechanism of edge restenosis in radioactive stents with an activity of 12 to 21 µCi that were implanted using a nonaggressive strategy.

Conclusions
Single ³²P radioactive ß-emitting stents with an initial activity of 12 to 21 µCi were more effective than 3 to 12 µCi stents in reducing intrastent neointimal hyperplasia, as measured by IVUS, but they did not solve the problem of edge restenosis, even if a nonaggressive stent implantation strategy was used. Edge restenosis in 12 to 21 µCi radioactive stents was mainly due to remodeling.

Received December 31, 1999; revision received April 5, 2000; accepted April 7, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Albiero R, Adamian M, Kobayashi N, et al. Short- and intermediate-term results of ³²P radioactive ß-emitting stent implantation in patients with coronary artery disease: the Milan dose-response study. Circulation. 2000;101:18–26.[Abstract/Free Full Text]
   
2. Janicki C, Duggan DM, Coffey CW, et al. Radiation dose from a phosphorous-32 impregnated wire mesh vascular stent. Med Phys. 1997;24:437–445.[Medline] [Order article via Infotrieve]
   
3. Nath R, Amols H, Coffey C, et al. Intravascular brachytherapy physics: report of the AAPM Radiation Therapy Committee Task Group No. 60: American Association of Physicists in Medicine. Med Phys. 1999;26:119–152.[Medline] [Order article via Infotrieve]
   
4. Reimers B, di Mario C, Di Francesco L, et al. New approach to quantitative angiographic assessment after stent implantation. Cathet Cardiovasc Diagn. 1997;40:343–347.[Medline] [Order article via Infotrieve]
   
5. Albiero R, Rau T, Schluter M, et al. Comparison of immediate and intermediate-term results of intravascular ultrasound versus angiography-guided Palmaz-Schatz stent implantation in matched lesions. Circulation. 1997;96:2997–3005.[Abstract/Free Full Text]
   
6. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676–1688.[Abstract/Free Full Text]
   
7. Powers BE, Thames HD, Gillette EL. Long-term adverse effects of radiation inhibition of restenosis: radiation injury to the aorta and branch arteries in a canine model. Int J Radiat Oncol Biol Phys. 1999;45:753–759.[Medline] [Order article via Infotrieve]
   

This article has been cited by other articles:

				A. V. Finn, F. D. Kolodgie, J. Harnek, L.J. Guerrero, E. Acampado, K. Tefera, K. Skorija, D. K. Weber, H. K. Gold, and R. Virmani Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents Circulation, July 12, 2005; 112(2): 270 - 278. [Abstract] [Full Text] [PDF]

				C. K. Prasad, K. R. Resmi, L. K. Krishnan, and R. Vaishnav Survival of Endothelial Cells in vitro on Paclitaxel-loaded Coronary Stents J Biomater Appl, April 1, 2005; 19(4): 271 - 286. [Abstract] [PDF]

				J. Fajadet, M.-C. Morice, C. Bode, P. Barragan, P. W. Serruys, W. Wijns, C. R. Constantini, J.-L. Guermonprez, H. Eltchaninoff, D. Blanchard, et al. Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial Circulation, March 1, 2005; 111(8): 1040 - 1044. [Abstract] [Full Text] [PDF]

				J. J. Popma, M. B. Leon, J. W. Moses, D. R. Holmes Jr, N. Cox, M. Fitzpatrick, J. Douglas, C. Lambert, M. Mooney, S. Yakubov, et al. Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Native Coronary Arteries Circulation, December 21, 2004; 110(25): 3773 - 3780. [Abstract] [Full Text] [PDF]

				P. W. Serruys, W. Wijns, G. Sianos, I. de Scheerder, P. A. van den Heuvel, W. Rutsch, H. D. Glogar, C. Macaya, P. H. Materne, S. Veldhof, et al. Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: Results of a randomized trial: Beta-radiation Investigation with Direct stenting and Galileo in Europe (BRIDGE) J. Am. Coll. Cardiol., August 4, 2004; 44(3): 528 - 537. [Abstract] [Full Text] [PDF]

				J. R Sindermann, V. Verin, J. W Hopewell, H. P. Rodemann, and J. H Hendry Biological aspects of radiation and drug-eluting stents for the prevention of restenosis Cardiovasc Res, July 1, 2004; 63(1): 22 - 30. [Abstract] [Full Text] [PDF]

				K. Krueger, M. Zaehringer, M. Bendel, H. Stuetzer, D. Strohe, M. Nolte, D. Wittig, R.-P. Mueller, and K. Lackner De Novo Femoropopliteal Stenoses: Endovascular Gamma Irradiation Following Angioplasty--Angiographic and Clinical Follow-up in a Prospective Randomized Controlled Trial Radiology, May 1, 2004; 231(2): 546 - 554. [Abstract] [Full Text] [PDF]

				P. W. Serruys, M. Degertekin, K. Tanabe, M. E. Russell, G. Guagliumi, J. Webb, J. Hamburger, W. Rutsch, C. Kaiser, R. Whitbourn, et al. Vascular Responses at Proximal and Distal Edges of Paclitaxel-Eluting Stents: Serial Intravascular Ultrasound Analysis From the TAXUS II Trial Circulation, February 10, 2004; 109(5): 627 - 633. [Abstract] [Full Text] [PDF]

				M. Degertekin, P. A. Lemos, C. H. Lee, K. Tanabe, J.E. Sousa, A. Abizaid, E. Regar, G. Sianos, W. J. van der Giessen, P. J. de Feyter, et al. Intravascular ultrasound evaluation after sirolimus eluting stent implantation for de novo and in-stent restenosis lesions Eur. Heart J., January 1, 2004; 25(1): 32 - 38. [Abstract] [Full Text] [PDF]

				J. M. A. Meyer, B. Nowak, K. Schuermann, A. Buecker, F. Moltzahn, A. Kulisch, N. Heussen, T. Gorgen, U. Bull, and R. W. Gunther Inhibition of Neointimal Proliferation with 188Re-labeled Self-Expanding Nitinol Stent in a Sheep Model Radiology, December 1, 2003; 229(3): 847 - 854. [Abstract] [Full Text] [PDF]

				C. O. Costantini, A. J. Lansky, G. S. Mintz, K. Shirai, G. Dangas, R. Mehran, M. Fahy, S. Slack, M. Coral, P. S. Teirstein, et al. Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions J. Am. Coll. Cardiol., May 21, 2003; 41(10): 1725 - 1731. [Abstract] [Full Text] [PDF]

				K. Tanabe, P. W. Serruys, E. Grube, P. C. Smits, G. Selbach, W. J. van der Giessen, M. Staberock, P. de Feyter, R. Muller, E. Regar, et al. TAXUS III Trial: In-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel Incorporated in a Slow-Release Polymer Formulation Circulation, February 4, 2003; 107(4): 559 - 564. [Abstract] [Full Text] [PDF]

				V. Spanos, G. Stankovic, J. Tobis, and A. Colombo The challenge of in-stent restenosis: insights from intravascular ultrasound Eur. Heart J., January 2, 2003; 24(2): 138 - 150. [Full Text] [PDF]

				E. Cheneau, R. Waksman, H. Yazdi, R. Chan, J. Fourdnadjiev, C. Berzingi, V. Shah, A. E. Ajani, L. Leborgne, and F. O. Tio How to Fix the Edge Effect of Catheter-Based Radiation Therapy in Stented Arteries Circulation, October 22, 2002; 106(17): 2271 - 2277. [Abstract] [Full Text] [PDF]

				T. Kataoka, E. Grube, Y. Honda, Y. Morino, S.-H. Hur, H. N. Bonneau, A. Colombo, C. Di Mario, G. Guagliumi, K. E. Hauptmann, et al. 7-Hexanoyltaxol-Eluting Stent for Prevention of Neointimal Growth: An Intravascular Ultrasound Analysis From the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE) Circulation, October 1, 2002; 106(14): 1788 - 1793. [Abstract] [Full Text] [PDF]

				M. Degertekin, P. W. Serruys, D. P. Foley, K. Tanabe, E. Regar, J. Vos, P. C. Smits, W. J. van der Giessen, M. van den Brand, P. de Feyter, et al. Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up Circulation, September 24, 2002; 106(13): 1610 - 1613. [Abstract] [Full Text] [PDF]

				S. H. Duda, B. Pusich, G. Richter, P. Landwehr, V. L. Oliva, A. Tielbeek, B. Wiesinger, J. B. Hak, H. Tielemans, G. Ziemer, et al. Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Six-Month Results Circulation, September 17, 2002; 106(12): 1505 - 1509. [Abstract] [Full Text] [PDF]

				P. W. Serruys, M. Degertekin, K. Tanabe, A. Abizaid, J. E. Sousa, A. Colombo, G. Guagliumi, W. Wijns, W. K. Lindeboom, J. Ligthart, et al. Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) Trial Circulation, August 13, 2002; 106(7): 798 - 803. [Abstract] [Full Text] [PDF]

				K. Krueger, P. Landwehr, M. Bendel, M. Nolte, H. Stuetzer, R. Bongartz, M. Zaehringer, G. Winnekendonk, A. Gossmann, R.-P. Mueller, et al. Endovascular Gamma Irradiation of Femoropopliteal de Novo Stenoses Immediately after PTA: Interim Results of Prospective Randomized Controlled Trial Radiology, August 1, 2002; 224(2): 519 - 528. [Abstract] [Full Text] [PDF]

				C. Haller Percutaneous coronary interventions in patients with renal failure: overcoming in-stent restenosis? Nephrol. Dial. Transplant., May 1, 2002; 17(5): 701 - 703. [Full Text] [PDF]

				P. Wexberg, C. Kirisits, M. Gyongyosi, M. Gottsauner-Wolf, M. Ploner, B. Pokrajac, R. Potter, and D. Glogar Vascular morphometric changes after radioactivestent implantation: a dose-response analysis J. Am. Coll. Cardiol., February 6, 2002; 39(3): 400 - 407. [Abstract] [Full Text] [PDF]

				A.J. Wardeh, R. Albiero, I.P. Kay, A.H.M. Knook, W. Wijns, K. Kozuma, T. Nishida, V. Ferrero, P.C. Levendag, W.J. van der Giessen, et al. Angiographical Follow-Up After Radioactive "Cold Ends" Stent Implantation: A Multicenter Trial Circulation, February 5, 2002; 105(5): 550 - 553. [Abstract] [Full Text] [PDF]

				P. S. Teirstein and R. E. Kuntz New Frontiers in Interventional Cardiology: Intravascular Radiation to Prevent Restenosis Circulation, November 20, 2001; 104(21): 2620 - 2626. [Full Text] [PDF]

				T. A. Fischell and R. Virmani Intracoronary Brachytherapy in the Porcine Model: A Different Animal Circulation, November 13, 2001; 104(20): 2388 - 2390. [Full Text] [PDF]

				C. Hehrlein, J. J. DeVries, A. Arab, S. D. Haller, K. Schloesser, F. O. Tio, and T. A. Fischell Failure of a Novel Balloon-Expandable {gamma}-Emitting (103Pd) Stent to Prevent Edge Effects Circulation, November 6, 2001; 104(19): 2358 - 2362. [Abstract] [Full Text] [PDF]

				W. J. van der Giessen, E. Regar, M. S. Harteveld, V. L.M.A. Coen, R. Bhagwandien, A. Au, P. C. Levendag, J. Ligthart, P. W. Serruys, A. den Boer, et al. "Edge Effect" of 32P Radioactive Stents Is Caused by the Combination of Chronic Stent Injury and Radioactive Dose Falloff Circulation, October 30, 2001; 104(18): 2236 - 2241. [Abstract] [Full Text] [PDF]

				G. S. Mintz, N. J. Weissman, and P. J. Fitzgerald Intravascular Ultrasound Assessment of the Mechanisms and Results of Brachytherapy Circulation, September 11, 2001; 104(11): 1320 - 1325. [Full Text] [PDF]

				T. Suzuki, G. Kopia, S.-i. Hayashi, L. R. Bailey, G. Llanos, R. Wilensky, B. D. Klugherz, G. Papandreou, P. Narayan, M. B. Leon, et al. Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model Circulation, September 4, 2001; 104(10): 1188 - 1193. [Abstract] [Full Text] [PDF]

				S.-W. Park, M.-K. Hong, D. H. Moon, S. J. Oh, C. W. Lee, J.-J. Kim, and S.-J. Park Treatment of diffuse in-stent restenosis with rotational atherectomy followed by radiation therapy with a rhenium-188-mercaptoacetyltriglycine-filled balloon J. Am. Coll. Cardiol., September 1, 2001; 38(3): 631 - 637. [Abstract] [Full Text] [PDF]

				S. O. Marx and A. R. Marks Bench to Bedside: The Development of Rapamycin and Its Application to Stent Restenosis Circulation, August 21, 2001; 104(8): 852 - 855. [Full Text] [PDF]

				G. Tepe, L. M. Dinkelborg, U. Brehme, P. Muschick, B. Noll, T. Dietrich, A. Greschniok, A. Baumbach, C. D. Claussen, and S. H. Duda Prophylaxis of Restenosis With 186Re-Labeled Stents in a Rabbit Model Circulation, August 6, 2001; 104(4): 480 - 485. [Abstract] [Full Text] [PDF]

				A. Arab, C. Bode, and C. Hehrlein The radioactive stent -- any chance of a resurrection? Eur. Heart J., August 1, 2001; 22(15): 1245 - 1247. [Abstract] [PDF]

				S. Parikh, D. Nori, R. Albiero, T. Nishida, M. Adamian, A. Amato, M. Vaghetti, N. Corvaja, C. Di Mario, and A. Colombo Edge Restenosis After Implantation of High Activity 32P Radioactive {beta}-Emitting Stents Response Circulation, April 10, 2001; 103 (14): e80 - e80. [Full Text] [PDF]

				R. Seabra-Gomes Radioactive stents to reduce restenosis: time for an epitaph? Eur. Heart J., April 2, 2001; 22(8): 621 - 623. [PDF]

				H.-S. Kim, R. Waksman, Y. Cottin, M. Kollum, B. Bhargava, R. Mehran, R. C. Chan, and G. S. Mintz Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1026 - 1030. [Abstract] [Full Text] [PDF]

				J. E. Sousa, M. A. Costa, A. Abizaid, A. S. Abizaid, F. Feres, I. M. F. Pinto, A. C. Seixas, R. Staico, L. A. Mattos, A. G. M. R. Sousa, et al. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries : A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study Circulation, January 16, 2001; 103(2): 192 - 195. [Abstract] [Full Text] [PDF]

				I. P. Kay, A. J. Wardeh, K. Kozuma, D. P. Foley, A. H. M. Knook, A. Thury, G. Sianos, W. J. van der Giessen, P. C. Levendag, and P. W. Serruys Radioactive Stents Delay but Do Not Prevent In-Stent Neointimal Hyperplasia Circulation, January 2, 2001; 103(1): 14 - 17. [Abstract] [Full Text] [PDF]

				P. S. Teirstein Fulfilling the Promise of Percutaneous Angioplasty Circulation, November 28, 2000; 102(22): 2674 - 2676. [Full Text] [PDF]

				F. Liistro, G. Stankovic, C. Di Mario, T. Takagi, A. Chieffo, S. Moshiri, M. Montorfano, M. Carlino, C. Briguori, P. Pagnotta, et al. First Clinical Experience With a Paclitaxel Derivate-Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome Circulation, April 23, 2002; 105(16): 1883 - 1886. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited